Cargando…

Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer

Background: PI3K/Akt/mTOR pathway is a crucial pathway in the angiogenesis, tumour growth and cell differentiation of several cancers. The PI3K and KIT genes are key genes of this pathway. Previous studies have reported the importance of these genes in the development of gastrointestinal carcinoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahimi, Maryam, Behjat, Farkhondeh, Taheri, Nazanin, Hosseini, Shadi, Khorram Khorshid, Hamid Reza, Aghakhani Moghaddam, Fatemeh, Karimlou, Masoud, Ghasemi, Saghar, Bazazzadegan, Niloofar, SiratI, Fereidoon, KeyhanI, Elahe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387810/
https://www.ncbi.nlm.nih.gov/pubmed/30815430
http://dx.doi.org/10.14196/mjiri.32.135
Descripción
Sumario:Background: PI3K/Akt/mTOR pathway is a crucial pathway in the angiogenesis, tumour growth and cell differentiation of several cancers. The PI3K and KIT genes are key genes of this pathway. Previous studies have reported the importance of these genes in the development of gastrointestinal carcinoma, leukaemia, and melanomas. The role of mutations and overexpression of PI3K and KIT genes in breast cancer has been previously proved. This study investigates the correlation between PI3K and KIT gene mutations in sporadic breast cancer. Methods: Multiplex Ligation-dependent Probe Amplification (MLPA) technique was used to determine the Copy Number Variation (CNV) of PI3K and KIT genes in 34 breast cancer tumours and PCR-sequencing was used to detect the mutation in PI3K exons 9 and 20. Results: Our results reported that 27% of patients had CNV of the KIT gene; whereas, 20% and 17.5% of patients, had mutation and CNV in the PI3K gene, respectively. We did not found a significant correlation between the mutations of PI3K and KIT genes. Conclusion: About two-tenth of the patients revealed CNV and lesser than two-tenth indicated mutation in the PI3K gene, whereas one-third of the patients demonstrated CNV in the KIT gene. Thus, administration of the PI3K and KIT gene inhibitor drugs might be proposed to suppress breast cancer in patients with mutation and CNV of each of these individual genes.